24/7 Customer Support

Asia Pacific Stem Cell Therapy Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2031

Asia Pacific Stem Cell Therapy Market: By Therapy Type (Autologous Stem Cell Therapy and Allogeneic Stem Cell Therapy); Product (Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs) and Very Small Embryonic Like Stem Cells); Cell Source (Adipose tissue-derived MSCs, Bone marrow derived MSCs, Placental/umbilical cord derived MSCs and Other Cell Sources); Technology (Cell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture; By Application- Musculoskeletal Disorders and others); End User (Hospitals, Research institutes and Others); and Country—Industry Dynamics, Market Size, and Opportunity Forecast for 2023–2031

  • Published Date: Feb-2023  |   Format: pdfpowerpointexcel  |  Report ID: AA0223362  | Delivery: 2 to 4 Hours


Autologous stem cell therapy, and allogeneic stem cell therapy are the two main types of therapies under the stem-cell therapy market that are expected to grow substantially in the future.

Major applications where stem-cell therapies are being used includes musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (AGVHD), surgeries, gastrointestinal diseases, cardiovascular diseases, inflammatory & autoimmune diseases, neurological disorders, and others.

The main benefits of stem-cell therapy include the treatment of cardiovascular diseases, helps in healing the incisions and wounds, progress in the treatment of neurogenerative diseases, autoimmune diseases, and in orthopaedic conditions as well, etc.

Stem cell therapies have gained a lot of popularity in recent years, as people look for the most cutting-edge alternative treatments for their various conditions. Through interdisciplinary & multidisciplinary research, clinical applications of engineered stem cells, transplantation, and the development of gene therapy, transplantation, the stem cell technology is advancing significantly. Stem cell research frequently makes use of technologies like stem cell culture, separation, and identification methods. Moreover, in recent years, experimental methods for stem cell isolation and culture have undergone significant development.

The Asia Pacific stem-cell therapy market is projected to grow at a CAGR of 10.29% during the forecast period 2023-2031 and is expected to reach US$ 3,420.05 million by 2031. 

Factor such as spurred demand for regenerative medicines, and funds availability for stem cell research drives the growth in the Asia Pacific stem-cell therapy market over the forecast period.

Allogeneic stem cell therapy segment holds the largest CAGR in the Asia Pacific stem-cell therapy market during the forecast period.

Problems associated with embryonic stem cells from an ethical standpoint inhibits the growth of the stem-cell therapy market during the forecast period, 2023-2031. 

China holds the major share in term of revenue in the Asia Pacific stem-cell therapy market.

Growing launches of novel products provides a lucrative growth opportunity in the Asia Pacific stem-cell therapy market.

Therapy Type, Product, Cell Source, Technology, Application, End User, and Country are different segments in the Asia Pacific stem-cell therapy market.

Brainstorm Cell Limited, AlloSource, Anterogen Co. Ltd., and Astellas Pharma Inc, among others are the major key players in the Asia Pacific stem-cell therapy market.